-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Secondary CNS Lymphoma Drug Details: Emavusertib hydrochloride is under development for the...
-
Product Insights
NewPapillary Renal Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Papillary Renal Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Papillary renal cell carcinoma (PRCC), a form of kidney cancer, originates in the tubes responsible for filtering waste from the blood. There are two subtypes: Type 1, more common and slow-growing, and type 2, aggressive and fast-growing. Symptoms may include blood in urine, pain, weight loss, fatigue, fever, or a palpable lump. Diagnosis involves imaging scans like CT, MRI, and...
-
Product Insights
NewSquamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
NewNon-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AU-314 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AU-314 in Metastatic Colorectal Cancer Drug Details: AU-314 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab Biosimilar in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab Biosimilar in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab Biosimilar in Metastatic Melanoma Drug Details: Pembrolizumab (Pembroria) is...
-
Product Insights
NewNet Present Value Model: Solid Biosciences Inc’s SGT-001
Empower your strategies with our Net Present Value Model: Solid Biosciences Inc's SGT-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – pVAX-hSlo in Urinary Incontinence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - pVAX-hSlo in Urinary Incontinence report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVAX-hSlo in Urinary Incontinence Drug Details: pVAX-hSlo (hmaxi-K) gene transfer therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZD-100 in Resistant Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ZD-100 in Resistant HypertensionDrug Details:ZD-100 is under development for the treatment of resistant hypertension. The drug...